Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Nov;36(5):464–466. doi: 10.1111/j.1365-2125.1993.tb00397.x

Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.

J I Schwartz 1, D J Margolskee 1, T D Bjornsson 1, V C Williams 1, J Y Hsieh 1, C C Lin 1, J D Rogers 1
PMCID: PMC1364621  PMID: 12959296

Abstract

The influence of dose and food on the pharmacokinetic profile of orally administered verlukast, a leukotriene D4 receptor antagonist, was investigated in 12 healthy male volunteers. This was an open, four-period, single dose, randomised, crossover design including the following doses: one 75 mg tablet, one 250 mg tablet, 500 mg (2 x 250 mg) and 500 mg immediately following a standard meal. There were dose-related increases in the AUC, although after 500 mg verlukast this was disproportionately greater than with 75 mg (P = 0.04). Similarly, there were dose-related increases in C(max). No differences were observed in the t(max) between treatments. With respect to food, there was a 22% decrease (P = 0.02) in C(max) after 500 mg, and the AUC was 13% less (P = 0.052). The differences in the plasma concentration profiles betweeen fasted and fed states are not considered to be of clinical importance.

Full text

PDF
464

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson K. E. Influences of diet and nutrition on clinical pharmacokinetics. Clin Pharmacokinet. 1988 Jun;14(6):325–346. doi: 10.2165/00003088-198814060-00002. [DOI] [PubMed] [Google Scholar]
  2. Depré M., Margolskee D. J., Van Hecken A., Hsieh J. S., Buntinx A., De Schepper P. J., Rogers J. D. Dose-dependent kinetics of the enantiomers of MK-571, and LTD4-receptor antagonist. Eur J Clin Pharmacol. 1992;43(4):431–433. doi: 10.1007/BF02220622. [DOI] [PubMed] [Google Scholar]
  3. Jones T. R., Zamboni R., Belley M., Champion E., Charette L., Ford-Hutchinson A. W., Frenette R., Gauthier J. Y., Leger S., Masson P. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17–28. doi: 10.1139/y89-004. [DOI] [PubMed] [Google Scholar]
  4. Lewis R. A., Austen K. F., Soberman R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990 Sep 6;323(10):645–655. doi: 10.1056/NEJM199009063231006. [DOI] [PubMed] [Google Scholar]
  5. Ludden T. M. Nonlinear pharmacokinetics: clinical Implications. Clin Pharmacokinet. 1991 Jun;20(6):429–446. doi: 10.2165/00003088-199120060-00001. [DOI] [PubMed] [Google Scholar]
  6. Manning P. J., Watson R. M., Margolskee D. J., Williams V. C., Schwartz J. I., O'Byrne P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. doi: 10.1056/NEJM199012203232504. [DOI] [PubMed] [Google Scholar]
  7. Margolskee D. J. Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist. Ann N Y Acad Sci. 1991;629:148–156. doi: 10.1111/j.1749-6632.1991.tb37972.x. [DOI] [PubMed] [Google Scholar]
  8. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet. 1978 Sep-Oct;3(5):337–351. doi: 10.2165/00003088-197803050-00001. [DOI] [PubMed] [Google Scholar]
  9. Robinett R. S., Hsieh J. Y. Stereoselective determination of R(-)- and S(+)-MK-571, a leukotriene D4 antagonist, in human plasma by chiral high-performance liquid chromatography. J Chromatogr. 1991 Sep 18;570(1):157–165. doi: 10.1016/0378-4347(91)80210-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES